

Eight Roads launches new \$400 M healthcare fund for China

30 June 2021 | News

The new fund will invest in and build innovative and transformational healthcare and life science companies



Eight Roads, the global investment firm backed by Fidelity, has announced the launch of its latest healthcare fund for China, Eight Roads China Healthcare Fund V. The \$400 million fund will follow Eight Roads' core strategy of healthcare investments in China, which is to develop a comprehensive healthcare ecosystem across the industry value chain and around critical diseases.

The new fund will invest in and build innovative and transformational healthcare and life science companies with disruptive technologies and innovative business models that address the unmet market demand. It will primarily focus on early-stage investment opportunities in the healthcare industry, covering therapeutics, med tech, healthcare services and healthcare IT/digital health.

Eight Roads has backed over 50 healthcare companies in China which sit across the healthcare industry value chain and have formed an ecosystem with strong synergetic effect. These investments span drug discovery and development (WuXi Apptec, Innovent Biologics, Hua Medicine, Adagene, Insilico Medicine, Westlake Therapeutics, Semma Therapeutics, OcuMension), domestic leading med tech (EyeBright, Nanos Medical, b-ONE, LenoMed, RedPine), traditional and innovative healthcare services (DeltaHealth, BangEr Orthopaedic Hospital, Gushengtang, Arion, TreeENT, OST, KnowYourself), and digital solutions that improve the efficiency of medical payment and health care (Medbanks, MediTrust, FuCunBao, Haici Technology, Wanhu Health).